Ladenburg Thalmann Financial Services’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-400
| Closed | – | – | 5397 |
|
|
2017
Q4 | $0 | Buy |
400
+250
| +167% | +$126 | ﹤0.01% | 5315 |
|
|
2017
Q3 | $0 | Hold |
150
| – | – | ﹤0.01% | 5251 |
|
|
2017
Q2 | $0 | Hold |
150
| – | – | ﹤0.01% | 5198 |
|
|
2017
Q1 | $0 | Hold |
150
| – | – | ﹤0.01% | 5198 |
|
|
2016
Q4 | $0 | Hold |
150
| – | – | ﹤0.01% | 5168 |
|
|
2016
Q3 | $0 | Hold |
150
| – | – | ﹤0.01% | 5133 |
|
|
2016
Q2 | $0 | Sell |
150
-825
| -85% | -$1.58K | ﹤0.01% | 5100 |
|
|
2016
Q1 | $1K | Hold |
975
| – | – | ﹤0.01% | 4665 |
|
|
2015
Q4 | $1K | Sell |
975
-1,165
| -54% | -$3.74K | ﹤0.01% | 4658 |
|
|
2015
Q3 | $16K | Buy |
2,140
+990
| +86% | +$7.57K | ﹤0.01% | 3264 |
|
|
2015
Q2 | $8K | Hold |
1,150
| – | – | ﹤0.01% | 3865 |
|
|
2015
Q1 | $10K | Hold |
1,150
| – | – | ﹤0.01% | 3685 |
|
|
2014
Q4 | $11K | Sell |
1,150
-590
| -34% | -$5.03K | ﹤0.01% | 3406 |
|
|
2014
Q3 | $17K | Buy |
+1,740
| New | +$25.8K | ﹤0.01% | 2808 |
|
|
2013
Q3 | – | Sell |
-400
| Closed | -$7K | – | 4022 |
|
|
2013
Q2 | $7K | Buy |
+400
| New | +$7.06K | ﹤0.01% | 2953 |
|
Ladenburg Thalmann Financial Services's RPRX Position: Q1 2018 in Review
Ladenburg Thalmann Financial Services sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 400 shares.
Ladenburg Thalmann Financial Services first reported a position in RPRX in Q2 2013 and held it in 15 quarters. The position peaked at $17K in Q3 2014. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Ladenburg Thalmann Financial Services reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Ladenburg Thalmann Financial Services sold 400 Repros Therapeutics Inc. shares in Q1 2018.
- Ladenburg Thalmann Financial Services first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 15 quarters.
- Ladenburg Thalmann Financial Services's Repros Therapeutics Inc. position peaked at $17K in Q3 2014.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2018, filed 15 May 2018.